CLINICAL CHARACTERISTICS AND CONCENTRATION OF CALPROTECTIN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATMENT AT THAI NGUYEN NATIONAL HOSPITAL

Abstract

This study aimed to describe clinical characteristics and determine the concentration of Calprotectin in the stool of Inflammatory Bowel Diseases (IBD). This study was a cross-sectional analysis of 34 patients with IBD and 20 patients with irritable bowel disease (control group) were clinically examined and collected stool samples from patients who tested Calprotectin on the LAISON-XL automated immunoassay. The results showed that the average Calprotetin concentration determining the IBD group and the control group was: 113.0±110.9mg/kg, respectively; 35.6±21.6 mg/kg. Calprotectin concentrations in patients with IBD were significantly higher than in controls with <0.001. The proportion of IBD patients with calprotectin concentration from 50-120 mg/kg, accounting for 58.8%, the proportion of patients with calprotectin concentration ≥ 120 mg/kg was 26.5%. The duration of the disease over 10 years accounted for the highest proportion (44.1%), symptoms of frequent bowel movements 3-4 times/day, bloody stools accounted for a high proportion. Based on clinical Mayo scores, mild disease activity accounted for 23.5%, moderate disease activity accounted for 41.3% and severe disease activity accounted for 35.3%. Endoscopic results rectal ulcerative lesions are the least common (20.6%). Left ulcerative colitis (41.2%), widespread ulcerative colitis (38.2%). In which, patients in stage 2 through Baron's endoscopic image accounted for 44.1%, stage 3 was 29.4% and only 23.5% of patients in stage 0.